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Abstract
Introduction Cardiac dysfunction is among the serious side
effects of therapy with recombinant humanized anti-erbB2
monoclonal antibody. The antibody blocks ErbB-2, a receptor
tyrosine kinase and co-receptor for other members of the ErbB
and epidermal growth factor families, which is over-expressed
on the surface of many malignant cells. ErbB-2 and its ligands
neuregulin and ErbB-3/ErbB-4 are involved in survival and
growth of cardiomyocytes in both postnatal and adult hearts,
and therefore the drug may interrupt the correct functioning of
the ErbB-2 pathway.
Methods The effect of the rat-anti-erbB2 monoclonal antibody
B-10 was studied in spontaneously beating primary myocyte
cultures from rat neonatal hearts. Gene expression was
determined by RT-PCR (reverse transcription polymerase chain
reaction) and by rat stress-specific microarray analysis, protein
levels by Western blot, cell contractility by video motion analysis,
calcium transients by the FURA fluorescent method, and
apoptosis using the TUNEL (terminal uridine nick-end labelling)
assay.
Results B-10 treatment induces significant changes in
expression of 24 out of 207 stress genes analyzed using the
microarray technique. Protein levels of ErbB-2, ErbB-3, ErbB-4
and neuregulin decreased after 1 day. However, both
transcription and protein levels of ErbB-4 and gp130 increased
several fold. Calreticulin and calsequestrin were overexpressed
after three days, inducing a decrease in calcium transients,
thereby influencing cell contractility. Apoptosis was induced in
20% cells after 24 hours.
Conclusion Blocking ErbB-2 in cultured rat cardiomyocytes
leads to changes that may influence the cell cycle and affects
genes involved in heart functions. B-10 inhibits pro-survival
pathways and reduces cellular contractility. Thus, it is
conceivable that this process may impair the stress response of
the heart.
Introduction
Human epidermal growth factor receptor (Her)-2 (ErbB-2), a
185 kDa transmembrane glycoprotein receptor with intrinsic
tyrosine kinase activity, is thought to be one of the important
mediators of cell growth [1-5]. It is overexpressed in 25–30%
of human breast cancers, plays a role in its pathogenesis and
is a predictive marker for poor prognosis in patients with met-
astatic disease [6-10].
Over recent years new therapies were developed to target
tumour cells with Her-2 overexpression by blocking Her-2 on
the cell surface of the tumour cells, thereby inhibiting their
growth. The most widely used drug based on this principle is
Trastuzumab (Herceptin®, Genentech Inc., San Francisco,
CA, USA), a high-affinity humanized anti-Her-2 antibody that
was shown to benefit patients with Her-2-overexpressing
breast cancer, either as a single agent or in combination with
chemotherapy [6,11,12]. In women who had received at least
one prior chemotherapeutic regimen for metastatic disease,
the response rate was found to be 15% and in previously
untreated patients 23%.
One of the major side effects noted was cardiotoxicity [6].
Congestive heart failure linked to Herceptin therapy may be
severe and has been associated with disabling symptoms. Of
patients receiving Herceptin together with paclitaxel, 12%
developed cardiac dysfunction, as compared with 1% receiv-
ing paclitaxel alone; the number increased further when Her-
ceptin was administered in combination with anthracyclines
(27%) compared with anthracyclines alone (7%) [6,13]. No
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data are yet available on identification of patients who are at
risk for developing cardiac dysfunction when they receive anti-
erbB2 therapy, although both prior cardiotoxic therapy (e.g.
radiation to the breast area) and advanced age may play a role.
ErbB-2 forms heterodimers with other ErbB receptors (ErbB-
3/ErbB-4) that can bind neuregulins, polypeptide growth fac-
tors that are known to promote survival and growth of cardiac
myocytes [14,15]. Thus, blocking ErbB-2 with a monoclonal
antibody may inhibit the myocardial adaptation to physiological
stress and injury, such as that resulting from chemoradiother-
apy, ultimately leading to cardiac failure in susceptible
patients.
In order to elucidate the molecular mechanisms that lead to
cardiotoxocity, we studied the effect of the rat-anti-erbB2
monoclonal antibody B-10 on spontaneously beating primary
cultures derived from rat neonatal hearts. B-10 has previously
been shown to have activity biologically similar to that of the
humanized antibody that is used in the clinical setting [16].
Materials and methods
Tissue culture
Neonatal rat ventricular muscle cells were prepared and plated
as described by Landau and coworkers [17]. Briefly, ventricles
from one-day-old rats were minced and treated with trypsin,
and the combined fractions were resuspended in growth
medium (Ham's F10 containing 10% foetal calf serum, 10%
horse serum, 200 U/ml penicillin, 200 µg/ml streptomycin,
135 mg/ml CaCl2 and 1 mmol/l glutamine; all from Biological
Industries, Kibbutz Bet Haemek, Israel) in a sterile flask (Nunc;
Nuclon Delta Herlev, Denmark) through a sterile mesh to
exclude explants. The pooled cells were suspended in growth
medium to a density of 9 × 105 to 1 × 106 cells/ml and seeded
into 30 mm diameter, six-well dishes (Falcon Labware, Oxnard,
CA, USA). After 24–36 hours, this concentration yielded a
near confluent layer of beating heart cells at a final density of
about 2 × 106 cells/ml. Cultures were kept at 37°C in an
atmosphere of 5% carbon dioxide and 95% air. Experiments
were performed at day 6, when more than 80% of the culture
consisted of myocardial cells. Cultures were serum starved for
24-hours before addition of the monoclonal antibody. (The
investigation conforms to the Guide for the Care and Use of
Laboratory Animals, published by the US National Institutes of
Health [18]).
B-10
Rat c-erbB-2/HER-2/neu Ab-9 (Neomarkers, Fremont, CA,
USA) was added at different concentrations (1.25 µg/ml to
7.5 µg/ml), to determine the optimal conditions by which the
cells will retain their structure and continue beating. Viability
was determined by Trypan blue exclusion analysis. The con-
centration of 5 µg/ml B-10 was chosen for all experiments;
treated cells were incubated at 37°C in an atmosphere of 5%
carbon dioxide and 95% air for 24 hours. Cells were harvested
with trypsin/EDTA and RNA was prepared using a commer-
cially available kit (Boehringer Mannheim-Roche, Basel,
Switzerland).
Reverse transcription polymerase chain reaction
The primers used in the study are summarized in Table 1.
Microarrays
To analyze gene expression, we used the Atlas™ Nylon cDNA
Rat stress Expression array (Clontech Pharmingen, Palo Alto,
CA, USA), containing 207 genes, in accordance with the man-
ufacturer's instructions. Analysis of the results was carried out
using software provided by Clontech.
Western blot analysis
Polyclonal antibodies to ErbB-2, ErbB-3, ErbB-4, neuregulin,
calreticulin, calsequestrin, gp130, akt, p-akt, β-actin and the
secondary antibodies were purchased from Santa Cruz Bio-
technology Inc. (Santa Cruz, CA, USA) and Jackson Laborato-
ries (Bar Harbor, Maine, USA) SDS-PAGE, transfer and
analysis were carried out in accordance with standard proce-
dures [19]. Briefly, proteins were separated on 5–15% SDS-
polyacrylamide gradient gels, and transferred to nitrocellulose
membranes using a Hoeffer transfer chamber. The mem-
branes were blocked with either 0.5% donkey serum or 2%
skim milk, depending on the antibody. Bands were detected
after incubation with Western Blotting Luminol reagent (Santa
Cruz Biotechnology Inc.).
Table 1
Primers used in the study
Gene Primers
ErbB-2 5'-TGGTGGTCGTTGGAATCCTAATC-3'
5'-CCAGCCATCACATACGCTTCATC-3'
ErbB-3 5'-GGTGCCAAAGGTCCAATCTA C-3'
5'-ACCGTCACCGCTATTACCAG-3'
ErbB-4 5'-CACAACCAGCACCATACCAG-3'
5'-TTCATCCAGTTCTGCTCGTG-3'
Neuregulin 5'-GAAGGCGCAAACACTTCTTC-3'
5'-TTGGCAACGATCACCAGTAA-3'
gp130 5'-TGAAGACAGACCATCCAAAGCG-3'
5'-CCATTCTACCCAGAGCAGGTTATC-3'
Calreticulin 5'-TCCCTGACCCTGATGCTAAGAAG-3'
5'-ATTGTGCCAGACTTGACCTGCC-3'
Calsequestrin 5'-CCAGAGCATCTGTGGACTCA-3'
5'-AGCCAGCAGACCTGAACAGT-3'
β-actin 5'-TTGTAACCAACTGGGACGATATGG-3'
5'-GATCTTGATCTTCATGGTGCTAGG-3'Available online http://breast-cancer-research.com/content/8/4/R35
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Cell contractility
Cultured cardiomyocytes were placed on the temperature-
controlled stage of an inverted microscope coupled to a video-
motion analyzer; cells were paced at a constant rate to control
for independent effects of changes in the beating rate. Analy-
sis was performed after marking manually the poles of one cell
pacing at 60/min; contractility is expressed as percentage
shortening.
Calcium transients
Calcium transients were determined by a modification to the
FURA fluorescence method [20].
TUNEL assay
TUNEL (terminal uridine nick-end labelling) assay was carried
out using the Promega DeadEnd™ Fluorometric TUNEL sys-
tem, in accordance with the manufacturer's instructions,
based on the method described by Ben-Sasson and cowork-
ers [21]. Slides were analyzed with a confocal laser scanning
microscope (Zeiss 410, Carl Zeiss GmbH, Goettingen Ger-
many). More than 1500 nuclei were counted per field; the
experiment was repeated three times.
Results
Tissue culture
The effect of B-10 on the morphology of neonatal rat ventricu-
lar heart muscle cells in vitro was determined by adding the
antibody at concentrations ranging between 1.25 µg/ml and
7.5  µg/ml. After 24 hours cells were analyzed visually.
Between concentrations of 1.25 µg/ml and 5 µg/ml, no differ-
ence in morphology and spontaneous beating could be
observed, whereas at concentrations higher than 5 µg/ml cells
appeared round and increased in size, no sharp intact cell
membrane could be detected and most cells had died. At 5
µg/ml B-10 cells retained their size and shape, but they
seemed to beat more slowly compared with untreated control
Table 2
Genes that are either upregulated or downregulated by B-10
Gene Up/downa
Mitogen-activated protein kinase 9 (MAPK9; PRKM9); c-jun N-terminal kinase 2 (JNK2); stress-activated protein kinase alpha 
(SAPK-α)
↑
Heat shock 27-kDa protein (HSP27) ↑
Heat shock 90-kDa protein beta (HSP90-β); HSP84; HSPCB ↑
Heat shock 60-kDa protein (HSP60); 60-kDa chaperonin (CPN60); GroEL homolog; mitochondrial matrix protein P1; p60 
lymphocyte protein
↑
Heat shock 47-kDa protein (HSP47); collagen-binding protein 1 (CBP1) ↓
HSP70/HSP90-organizing protein (HOP); p60 protein ↓
Heat shock 10-kDa protein (HSP10); chaperonin 10 (CPN10) ↓
p23; 23-kDa progesterone receptor-associated protein (rat homologue of human) ↓
Vimentin (VIM) ↑
T-complex protein 1 alpha subunit (TCP1-α); CCT-alpha (CCTA; CCT1) ↓
T-complex protein 1 eta subunit (TCP1-eta); CCT-eta (CCTH; CCT7); HIV-1 NEF interacting protein (rat homologue of human) ↑
Calreticulin (CALR); calregulin; calcium-binding protein 3 (CABP3); HACBP; ERP60 ↑
Endoplasmic reticulum stress protein 72 (ERP72); calcium-binding protein 2 (CABP2) ↓
M-phase inducer phosphatase 2 (MPI2); cell division control protein 25 B (CDC25B) ↓
G1/S-specific cyclin D2 (CCND2); vin-1 proto-oncogene ↑
G1/S-specific cyclin D3 (CCND3) ↓
G2/M-specific cyclin G (CCNG) ↑
Inhibitor of DNA binding 1 (ID1) ↑
Inhibitor of DNA binding 2 (ID2) ↓
Prothymosin-alpha (PTMA) ↑
Soluble superoxide dismutase 1 (SOD1) ↓
DNA topoisomerase I (TOP1; rat homologue of human) ↑
Nucleophosmin (NPM); nucleolar phosphoprotein B23; numatrin; nucleolar protein NO38 ↓
Ribosomal protein S19 (RPS19) ↓
aUpregulated (↑) or downregulated (↓).Breast Cancer Research    Vol 8 No 4    Pugatsch et al.
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cells. Cell viability, as determined by Trypan blue exclusion
analysis, was 89%, which is comparable to that of untreated
control cells; therefore, the concentration of 5 µg/ml was cho-
sen for all subsequent experiments.
Gene expression
Of the 207 genes tested, the expression of 24 was modulated
by the antibody (Table 2). Most prominently affected were pro-
teins involved in the cell cycle, a number of the heat shock pro-
teins and proteins involved in calcium exchange.
Figure 1
RT-PCR analysis of control and treated (B-10) cells RT-PCR analysis of control and treated (B-10) cells. Primers used are described in Table 1. RT-PCR, reverse transcription polymerase chain 
reaction.
Figure 2
Western blot analysis of control and treated (B-10) cells after 24/72 hours Western blot analysis of control and treated (B-10) cells after 24/72 hours.Available online http://breast-cancer-research.com/content/8/4/R35
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We further analyzed different members of the ErbB family, two
known ligands for ErbB-2 (neuregulin and gp130), and calre-
ticulin and calsequestrin using both RT-PCR (Figure 1) and
Western blot analyses (Figure 2).
Twenty-four hours after incubation, B-10 substantially down-
regulated the transcription of ErbB-2 (fourfold) as well as that
of ErbB-3, whereas transcription of ErbB-4 was increased
(Figure 2); ErbB-2 itself, as expected, as well as both ErbB-3
and ErbB-4 were downregulated at the translational levels
(Table 3).
In the microarray analysis, we found that calreticulin, a calcium
storage protein in the sarcoplasmatic reticulum, was upregu-
lated. Although this protein is necessary for heart development
in the embryo, it is usually not expressed in the adult cell [22].
As shown in Figure 1, upon administration of B-10 calreticulin
transcription increased threefold. No change could be
detected at the protein level after one day; however, after three
days its level increased compared with that in control cells
(Figure 2). Whereas no effect on both calsequestrin transcrip-
tion and translation was detected after one day, protein levels
were higher after three days (Figures 1 and 2, Table 3).
We then analyzed two additional ligands of ErbB-2, namely
neuregulin and gp130. Both transcription and translation of
neuregulin were downregulated nearly twofold, whereas
gp130 mRNA levels increased at least threefold. The protein
levels of neuregulin are consistent with the RT-PCR finding.
Surprisingly, hardly any difference could be detected in the
protein levels of gp130; in fact, we noticed a slight decrease
(Figures 1 and 2, Table 3).
As representatives of the cell survival pathway, we chose to
determine the levels of akt-1 and p-akt-1 in B-10 treated car-
diomyocytes. As shown in Figure 2, no effect was seen on p-
akt-1, whereas akt-1 expression was slightly but not signifi-
cantly lower than that of control cells.
Cell contractility and calcium transients
The antibody severely interferes with cell contractility, which
was reduced by 40% compared with that in control cells (Fig-
ure 3). The difference in calcium transients between treated
and control cells reached 20% (Figure 4).
Apoptosis
Both treated cells and control cultures were analyzed for
induction of apoptosis 24 hours after adding B-10 or doxoru-
bicin (10 µmol/l). B-10 treated cells underwent rapid apopto-
sis (20 ± 0.09%) compared with doxorubicin-treated positive
control cells (98 ± 0.09%), and very little apoptosis in
untreated control cells (2.35 ± 0.02%; Figures 5 and 6).
Figure 3
Contraction, as assessed by percentage shortening Contraction, as assessed by percentage shortening. The values (mean 
± standard deviation) are as follows: control 0.3037 ± 0.0096 and B-
10 treatment 0.1842 ± 0.0205. P < 0.001.
Figure 4
Calcium transient analysis Calcium transient analysis. The values (relative absorbance; mean ± 
standard deviation) are as follows: control 0.803 ± 0.04 and B-10 
0.644 ± 0.04. P < 0.001.
Table 3
Summary of RT-PCR and Western blot analysis
RT-PCR Western blot
1 day 3 days
ErbB-2 ↓↓ND
ErbB-3 ↓↓ND
ErbB-4 ↑↓ND
Calreticulin ↑ = ↑
Calsequestrin = = ↑
Gp130 ↑↓ND
Neu ↓↓ND
Akt ND = ND
p-Akt ND = ND
↑, upregulated; ↓, downregulated; =, no change; ND, not 
determined; RT-PCR, reverse transcription polymerase chain 
reaction.Breast Cancer Research    Vol 8 No 4    Pugatsch et al.
Page 6 of 8
(page number not for citation purposes)
Discussion
Targeted monoclonal antibody therapy as a biological treat-
ment for different cancers appears to have many advantages
over conventional chemo/radiotherapy. In the case of ErbB-2
overexpressing breast cancer cells, it was postulated that anti-
body therapy would specifically eliminate only tumour cells
without affecting any other ErbB-2 expressing cells [23-25].
Although erbB-2 is expressed ubiquitously, it was thought that
those levels are sufficiently low not to be affected by anti-erbB-
2 antibodies. However, ErbB-2 plays a vital role both in devel-
oping and in adult murine cardiomyocytes [14,26-28]. ErbB-2
null mutant mice exhibit an absence of trabecules in the heart
ventricle and die at midgestation [14]. Adult mice carrying a
conditional ErbB-2 mutation develop severe dilated cardiomy-
opathy, usually in the second month of life [28]. As shown by
Özcelik and coworkers [29], loss of ErbB-2 in cardiomyocytes
leads to physiological stress on the heart, which over time
induces cardiac decompensation and dilated cardiomyopathy.
The effect of trastuzumab on cells on the molecular level has
repeatedly been analyzed on human breast cancer cell lines
[30,31]. However, to our knowledge very few molecular stud-
ies on the effect of the antibody on cardiomyocytes have been
reported. In vitro cultures of primary human cardiomyocytes
are not readily attainable for both ethical and technical rea-
sons. Therefore, in our study we opted to use the generally
accepted in vitro model of neonatal rat ventricular heart mus-
cle cells. Trastuzumab, being a humanized monoclonal anti-
body, does not bind to rat cells, consequently we used B-10
instead, which was shown previously to have biologic activity
similar to that of trastuzumab [16,32]. Our results reveal a sub-
stantial decrease in the level of all ErbB family members
analyzed after treatment with B-10. ErbB-2 by itself has no
tyrosine kinase activity and needs to form heterodimers with
one of its ligands to be functional [33]. All the ligands tested
in our system were downregulated, thereby affecting the cen-
t r a l  r o l e  p l a y e d  b y  E r b B - 2  in the heart. Moreover, gp130,
which is thought to bind to ErbB-2 after biomechanical stress
(hypoxia, haemodynamic overload and myocardial injury,
among other insults) and activates a survival pathway [34], is
strongly affected by B-10. Our results imply that the turnover
of gp130 is augmented, as reflected in the several fold
increase in transcription; nevertheless, the decrease in gp130
cannot be completely compensated.
Figure 5
TUNEL assay, 24 hours after addition of B-10 or doxorubicin TUNEL assay, 24 hours after addition of B-10 or doxorubicin. The first row shows untreated control cells. The second row shows doxorubicin (10 
µmol/l) treated positive control cells. The third row shows B-10 treated cells. TUNEL, terminal uridine nick-end labeling.Available online http://breast-cancer-research.com/content/8/4/R35
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It was previously demonstrated that overexpression of calreti-
culin modulates protein kinase B/Akt signalling, promoting
apoptosis during cardiac differentiation of cardiomyoblasts
[35]. In our system B-10 induced an increase in both calreti-
culin and calsequestrin levels three days after antibody treat-
ment. The high levels of both of these calcium storage proteins
in the sarcoplasmic reticulum may modify calcium release and
subsequently lead to reduced cell contractility, decreasing the
percentage shortening by 40%. This finding corroborates the
studies described in ErbB-2 mutant mice and calsequestrin
overexpressing mice [36,37]. Sawyer and coworkers [38],
when comparing anthracycline- and ErbB2-induced myofibril-
lar disarray, reported no effect of B-10 on either akt or p-akt in
cultures of adult rat ventricular myocytes, which is consistent
with our data.
Finally, apoptosis may be a factor in the loss of ventricular
function that is part of the cardiotoxic side effect profile of anti-
erbB2 monoclonal antibody therapy. In our system B-10-
induced apoptosis was three times greater than that recently
described by Grazette and coworkers [39]. However, those
investigators used a different antibody (clone 9G6), which
may account for the difference in intensity.
Conclusion
In this molecular analysis of the effects of B-10 on neonatal
cardiomyocytes, we demonstrated that the rat-anti-erbB2
monoclonal antibody B-10 severely affects ErbB-2 and its
major ligands ErbB-3/4, neuregulin and gp130. In addition, the
drug promotes increased expression of calreticulin and calse-
questrin, which are involved in the sarcoplasmatic reticulum
calcium pump and decrease cell contractility, which in vivo
may lead to dilated cardiomyopathy in mice and humans as
described previously [22,28,34,40]. Despite being present at
a low level, in cardiomyocytes ErbB-2 plays a central role in the
correct functioning of the cell. Blocking ErbB-2 by a mono-
clonal antibody disrupts the cell survival pathways and the
ErbB-signalling network that depends on the relative stoichi-
ometry between all of the players involved. We therefore spec-
ulate that this process may impair the stress response of the
heart.
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